- Home
- HIT vs IMA Comparison
HIT vs IMA Comparison
Compare HIT & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIT | IMA |
|---|---|---|
| Founded | 1964 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.1M | 66.3M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HIT | IMA |
|---|---|---|
| Price | $1.00 | $5.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $3.25 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 67.6K | 8.0K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,327,511.00 | $800,000.00 |
| Revenue This Year | $41.00 | N/A |
| Revenue Next Year | $69.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 70.99 | N/A |
| 52 Week Low | $0.85 | $3.94 |
| 52 Week High | $4.01 | $14.34 |
Technical Indicators
Market Signals| Indicator | HIT | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 47.80 |
| Support Level | $0.99 | $5.36 |
| Resistance Level | $1.16 | $6.11 |
| Average True Range (ATR) | 0.06 | 0.30 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 10.10 | 47.22 |
Price Performance
Historical ComparisonAbout HIT Health In Tech Inc.
Health In Tech Inc is an AI-enabled insurance technology platform company that offers a marketplace that improves processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, it streamlines the underwriting, sales, and service process for insurance companies, licensed brokers, Managing General Underwriter (MGUs), and third-party administrators (TPAs). The company's platform serves as a marketplace for brokers, TPAs, MGUs and carriers with self-funded health insurance options for employers. The platform includes functions such as plan customization, stop-loss quoting, underwriting, claims administration, and reporting integration.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.